Inhibition of NF-κB by a PXR-dependent pathway mediates counter-regulatory activities of rifaximin on innate immunity in intestinal epithelial cells

European Journal of Pharmacology

Volumn 668, Issue 1-2, 2011, Pages 317-324

  Mencarelli, Andrea ^a   Renga, Barbara ^a   Palladino, Giuseppe ^a   Claudio, D'Amore ^a   Ricci, Patrizia ^a   Distrutti, Eleonora ^b   Barbanti, Miriam ^c   Baldelli, Franco ^b   Fiorucci, Stefano ^a  

^a UNIVERSITY OF PERUGIA   (Italy)

^b SANTA MARIA DELLA MISERICORDIA HOSPITAL   (Italy)

^c Alfa Wassermann SpA   (Italy)

Author keywords

Chemokines; Inflammatory bowel diseases; Intestinal epithelial cells; Pregnane X receptor (PXR); Rifaximin

Indexed keywords

AZATHIOPRINE; BUDESONIDE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; LIPOPOLYSACCHARIDE; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MESSENGER RNA; PREGNANE X RECEPTOR; PROSTAGLANDIN E2; RANTES; RIFAXIMIN; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; COLON BIOPSY; CONTROLLED STUDY; CROHN DISEASE; DRUG EFFECT; DRUG EXPOSURE; ENTEROBACTERIACEAE; FEMALE; FETUS; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; INNATE IMMUNITY; INTESTINE EPITHELIUM CELL; MALE; MUCOSAL IMMUNITY; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; PROTEIN BINDING; PROTEIN EXPRESSION;

CELL LINE; CHEMOKINES; COLON; DNA; GENE REGULATORY NETWORKS; GENE SILENCING; HUMANS; IMMUNITY, INNATE; INTESTINAL MUCOSA; LIPOPOLYSACCHARIDES; NF-KAPPA B; RECEPTORS, STEROID; RIFAMYCINS; SIGNAL TRANSDUCTION;

EID: 80052052440     PISSN: 00142999     EISSN: 18790712     Source Type: Journal    
DOI: 10.1016/j.ejphar.2011.06.058     Document Type: Article

References (29)

1. D. Artis Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut Nat. Rev. Immunol. 8 2008 411 420 (Pubitemid 351733416)
2. N.M. Bass, K.D. Mullen, A. Sanyal, F. Poordad, G. Neff, C.B. Leevy, S. Sigal, M.Y. Sheikh, K. Beavers, T. Frederick, L. Teperman, D. Hillebrand, S. Huang, K. Merchant, A. Shaw, E. Bortey, and W.P. Forbes Rifaximin treatment in hepatic encephalopathy N. Engl. J. Med. 362 2010 1071 1081
3. A.L. Bookout, Y. Jeong, M. Downes, R.T. Yu, R.M. Evans, and D.J. Mangelsdorf Anatomical profiling of nuclear receptor expression reveals a hierarchical transcriptional network Cell 126 2006 789 799 (Pubitemid 44233630)
4. E. Cario, and D.K. Podolsky Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and TLR4 in inflammatory bowel disease Infect. Immun. 68 2000 7010 7017 (Pubitemid 32463415)
5. J. Cheng, Y.M. Shah, X. Ma, X. Pang, T. Tanaka, T. Kodama, K.W. Krausz, and F.J. Gonzalez Therapeutic role of Rifaximin in inflammatory bowel disease: Clinical implication of human pregnane X receptor activation J. Pharmacol. Exp. Ther. 335 2010 32 41
6. M.M. Dring, C.A. Goulding, V.I. Trimble, D. Keegan, A.W. Ryan, K.M. Brophy, C.M. Smyth, P.W. Keeling, D. O'Donoghue, M. O'Sullivan, C. O'Morain, N. Mahmud, A.C. Wikström, D. Kelleher, and R. McManus The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease Gastroenterology 130 2006 341 348 (Pubitemid 43202034)
7. H.L. DuPont, R. Haake, D.N. Taylor, C.D. Ericsson, Z.D. Jiang, P.C. Okhuysen, and R. Steffen Rifaximin treatment of pathogen-negative travelers' diarrhea J. Travel Med. 14 1 2007 16 19 (Pubitemid 46114982)
8. D. Franchimont, S. Vermeire, H. El Housni, M. Pierik, K. Van Steen, T. Gustot, E. Quertinmont, M. Abramowicz, A. Van Gossum, J. Devière, and P. Rutgeerts Deficient host-bacteria interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly polymorphism is associated with Crohn's disease and ulcerative colitis Gut 53 2004 987 992 (Pubitemid 38824157)
9. C. Garlanda, F. Riva, N. Polentarutti, C. Buracchi, M. Sironi, M. De Bortoli, M. Muzio, R. Bergottini, E. Scanziani, A. Vecchi, E. Hirsch, and A. Mantovani Intestinal inflammation in mice deficient in Tir8, an inhibitory member of the IL-1 receptor family Proc. Natl. Acad. Sci. U. S. A. 101 2004 3522 3526 (Pubitemid 38338228)
10. X. Gu, S. Ke, D. Liu, T. Sheng, P.E. Thomas, A.B. Rabson, M.A. Gallo, W. Xie, and Y. Tian Role of NF-kappaB in regulation of PXR-mediated gene expression, a mechanism for the suppression of cytochrome P-4503A4 by pro-inflammatory agents J. Biol. Chem. 281 2006 17882 17889 (Pubitemid 44035587)
11. W.W. Hoover, E.H. Gerlach, D.J. Hoban, G.M. Eliopoulos, M.A. Pfaller, and R.N. Jones Antimicrobial activity and spectrum of rifaximin, a new topical rifamycin derivative Diagn. Microbiol. Infect. Dis. 16 1993 111 118 (Pubitemid 23090031)
12. M.W. Hornef, T. Frisan, A. Vandewalle, S. Normark, and A. Richter-Dahlfors Toll-like receptor 4 resides in the golgi apparatus and colocalizes with internalized lipopolysaccharide in intestinal epithelial cells J. Exp. Med. 195 2002 559 570 (Pubitemid 34461501)
13. J.P. Hugot, M. Chamaillard, H. Zouali, S. Lesage, J.P. Cézard, J. Belaiche, S. Almer, C. Tysk, C.A. O'Morain, M. Gassull, V. Binder, Y. Finkel, A. Cortot, R. Modigliani, P. Laurent-Puig, C. Gower-Rousseau, J. Macry, J.F. Colombel, M. Sahbatou, and G. Thomas Association of NOD2 leucinerich repeat variants with susceptibility to Crohn's disease Nature 411 2001 599 603 (Pubitemid 32531408)
14. Z.D. Jiang, and H.L. DuPont Rifaximin: in vitro and in vivo antibacterial activity Chemotherapy 51 2005 67 72 (Pubitemid 40663191)
15. Z.D. Jiang, S. Keb, and H.L. DuPont Rifaximin-induced alteration of virulence of diarrhoea-producing Escherichia coli and Shigella sonnei Int. J. Antimicrob. Agents 35 2010 278 281
16. D. Kelly, J.I. Campbell, T.P. King, G. Grant, E.A. Jansson, A.G. Coutts, S. Pettersson, and S. Conway Commensal anaerobic gut bacteria attenuate inflammation by regulating nuclear-cytoplasmic shuttling of PPARgamma and RelA Nat. Immun. 5 2004 104 112 (Pubitemid 38081475)
17. T. Langmann, C. Moehle, R. Mauerer, M. Scharl, G. Liebisch, A. Zahn, W. Stremmel, and G. Schmitz Loss of detoxification in inflammatory bowel disease: dysregulation of pregnane X receptor target genes Gastroenterology 127 2004 26 40 (Pubitemid 38962271)
18. X. Ma, Y.M. Shah, G.L. Guo, T. Wang, K.W. Krausz, J.R. Idle, and F.J. Gonzalez Rifaximin is a gut-specific human pregnane X receptor activator J. Pharmacol. Exp. Ther. 322 2007 391 398 (Pubitemid 46956365)
19. A. Mencarelli, M. Migliorati, M. Barbanti, S. Cipriani, G. Palladino, E. Distrutti, B. Renga, and S. Fiorucci Pregnane-X-receptor mediates the anti-inflammatory activities of rifaximin on detoxification pathways in intestinal epithelial cells Biochem. Pharmacol. 80 2010 1700 1707
20. K.A. Papadakis, and S.R. Targan The role of chemokines and chemokine receptors in mucosal inflammation Inflamm. Bowel Dis. 6 2000 303 313
21. M. Pimentel, A. Lembo, W.D. Chey, S. Zakko, Y. Ringel, J. Yu, S.M. Mareya, A.L. Shaw, E. Bortey, W.P. Forbes TARGET Study Group Rifaximin therapy for patients with irritable bowel syndrome without constipation N. Engl. J. Med. 364 2011 22 32
22. D.K. Podolsky Mucosal immunity and inflammation. V. Innate mechanisms of mucosal defense and repair: the best offense is a good defense Am. J. Physiol. 277 1999 G495 499
23. C. Prantera, H. Lochs, M. Campieri, M.L. Scribano, G.C. Sturniolo, F. Castiglione, and M. Cottone Antibiotic treatment of Crohn's disease: results of a multicentre, double blind, randomized, placebo-controlled trial with rifaximin Aliment. Pharmacol. Ther. 23 2006 1117 1125 (Pubitemid 43779351)
24. C. Prantera, H. Lochs, P. Gionchetti, M. Campieri, S. Danese, M. Fogli, M.L. Scribano, and M. Grimaldi Rifaximin-EIR (Extended Intestinal Release) 400 mg tablets in the treatment of moderately active crohn's disease: results of the international multicentre, randomised, double-blind, placebo-controlled trial retic-03 Gut 59 Suppl. III 2010
25. M. Rimoldi, M. Chieppa, V. Salucci, F. Avogadri, A. Sonzogni, G.M. Sampietro, A. Nespoli, G. Viale, P. Allavena, and M. Rescigno Intestinal immune homeostasis is regulated by the crosstalk between epithelial cells and dendritic cells Nat. Immunol. 6 2005 507 514 (Pubitemid 41716764)
26. C. Scarpignato, and I. Pelosini Experimental and clinical pharmacology of Rifaximin, a gastrointestinal selective antibiotic Digestion 73 Suppl 1 2006 13 27
27. S.K. Yang, L. Eckmann, A. Panja, and M.F. Kagnoff Differential and regulated expression of C-X-C, C-C, and C-chemokines by human colon epithelial cells Gastroenterology 113 1997 1214 1223 (Pubitemid 27418975)
28. C. Zhou, M.M. Tabb, E.L. Nelson, F. Grün, S. Verma, A. Sadatrafiei, M. Lin, S. Mallick, B.M. Forman, K.E. Thummel, and B. Blumberg Mutual repression between steroid and xenobiotic receptor and NF-kappaB signaling pathways links xenobiotic metabolism and inflammation J. Clin. Invest. 116 2006 2280 2289 (Pubitemid 44162338)
29. N.P. Zimmerman, R.A. Vongsa, M.K. Wendt, and M.B. Dwinell Chemokines and chemokine receptors in mucosal homeostasis at the intestinal epithelial barrier in inflammatory bowel disease Inflamm. Bowel Dis. 14 2008 1000 1011